Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ascletis Pharma Inc.

www.ascletis.com

Latest From Ascletis Pharma Inc.

GSK Opts In On Ionis’ Antisense Candidates For Hep B

The pharma is taking over a pair of Ionis candidates intended to address the underlying cause of HBV, possibly offering a curative therapy. It’s just the second HBV licensing agreement in 2019, after heavier deal flow in recent years.

Deals Infectious Diseases

Finance Watch: Landos Raises $60m Series B Round Ahead Of Phase II Data In 2020

If Landos goes public late next year, its financing strategy will align with venture capital and IPO trends observed in a new Jefferies report. Also, D&D Pharmatech raises $137.1m in VC cash, Sonnet secures up to $100m and the CF Foundation commits up to $15m to Arcturus.

Financing Business Strategies

Asia Executives On The Move: Returners And Leavers At Merck; Changes At Takeda, Ono, Simcere And More

Merck China former R&D head returns after a short stint with startup Ascletis, and Takeda has a new center director for commercial health. Top executives change also take place at Ono in Korea and Simcere Pharma.

Asia Pacific Appointments

Trade War Expansion? STAR Board Aims To Keep Lucrative China Biotech IPOs At Home

China has officially unveiled its newest stock market for pre-revenue high-tech companies, already attracting ChipScreen and marking a new rival to similar bourses in the US and Hong Kong. But some are cautioning that local regulators and investors will need to step up if the so-called China Nasdaq is to gain traction.

China Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Ascletis Pharma Inc.
  • Senior Management
  • Jinzi J Wu, PhD, Pres. & CEO
    Yuemei Yan, VP, Sales
    Zhengqing Li, PhD, CMO
  • Contact Info
  • Ascletis Pharma Inc.
    Phone: 571- 8538-9729
    1785 Jianghai Rd., Bldg. 4, Ste. 1801
    Hangzhou, NC
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register